Munich Re’s global medical team recently collaborated on a wide-ranging thought leadership project intended to help life insurers better understand and navigate the most prevalent emerging medical trends and risks across five critical topics: AI in Healthcare, Improving Cancer Outcomes, Prevention, Obesity, and Climate Change.
The Obesity chapter examines how new anti-obesity medications can reduce obesity-related mortality and morbidity risks. As many adverse medical conditions are associated with obesity, if these medications can stop or reverse the upward obesity prevalence trends, the potential impacts on mortality and morbidity could be significant, with an impact on life, disability, and critical illness portfolios.
Key takeaways
- Forecasted obesity trends: Obesity prevalence continues to rise, with forecasts predicting that more than half of the global population will be obese by 2035. This trend poses significant risks to health outcomes and insurance portfolios.
- Impact of new medications: If these medications can stop or reverse the upward obesity prevalence trends, the potential impacts on mortality and morbidity could be huge.
- Weight loss outcomes: The current literature on newer drugs for adults with obesity supports weight loss outcomes never seen with prior weight loss medications.
- Impact on insurance portfolios: This chapter provides a plausible estimation of the revolutionary impact weight loss medications may have on life, disability, and critical illness portfolios.
Visit our Life Science Report page for more information and to access additional chapters.
Sponsored by ITL Partner: Munich Re
